Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy
G Ndrepepa, A Kastrati - Journal of Clinical Medicine, 2023 - mdpi.com
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
Tongxinluo capsule as a multi-functional traditional Chinese medicine in treating cardiovascular disease: A review of components, pharmacological mechanisms, and …
J Xin, T Wang, B Hou, X Lu, N Han, Y He, D Zhang… - Heliyon, 2024 - cell.com
Cardiovascular diseases (CVDs) are one of the most significant diseases that pose a threat
to human health. The innovative traditional Chinese medicine Tongxinluo Capsule …
to human health. The innovative traditional Chinese medicine Tongxinluo Capsule …
Coronary No-reflow After Primary Percutaneous Coronary Intervention–Current knowledge on Diagnosis, Pathophysiology, Clinical Impact and Therapy
G Ndrepepa, A Kastrati - 2023 - preprints.org
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
Investigating the role of SIRT3 in doxorubicin induced dilated cardiomyopathy
M Tomczyk - 2023 - mspace.lib.umanitoba.ca
Doxorubicin (DOX) is an effective anthracycline anti-neoplastic agent used for the treatment
of hematological and solid tumors. Advancements in cancer treatment over several decades …
of hematological and solid tumors. Advancements in cancer treatment over several decades …